Navigation Links
Bradmer announces 2008 fourth quarter and fiscal year operational and financial results
Date:3/31/2009

TSX: BMR

TORONTO, March 31 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc. ("Bradmer" or the "Corporation") announced its 2008 fourth quarter and fiscal year operational and financial results.

Operational Highlights

During the year ended December 31, 2008, the Company achieved the following steps for its multi-center Phase III trial of its lead drug Neuradiab(R), a treatment for glioblastoma multiforme (GBM), the most advanced form of brain cancer:

    -   Prepared and submitted the Company's drug manufacturing data package
        and clinical dossiers to the FDA;
    -   Initiated enrollment in the Phase III GLASS-ART clinical trial;
    -   Signed contracts with and activated an initial cohort of five U.S.
        clinical trial sites;
    -   Successfully released a second GMP drug substance batch for use in
        clinical trials and filed the related update with the FDA;
    -   Submitted new data from the previous Phase II trial indicating that
        the mean time to progression free survival was 77 weeks, which
        compares favorably with other published results in newly diagnosed
        GBM (Reardon et al.; 2008 Neuro-Oncology 10:845); and
    -   Sourced and validated commercial supplies of iodine-131 outside of
        the U.S. and Europe to prevent delays in raw material supply.

Subsequent to the financial year ended December 31, 2008, the Company commenced a strategic review of its operations, as more particularly described in press releases of the Company dated February 17, 2009 and March 5, 2009. Pursuant to the strategic review, the Company has closed its Phase III GLASS ART Trial to further patient enrollment due to unforeseen delays in site initiation and recruitment, the delayed ability to complete the 60 patient "run-in phase" in a timely manner, and the inability to raise further capital at this time.

The Company
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Bradmer implements cash conservation plan
2. Bradmer provides clinical trial update and announces evaluation of strategic alternatives
3. Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference
4. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
5. Bradmer announces 2008 third quarter operational and financial results
6. Bradmer to present at Rodman & Renshaw Healthcare Conference
7. Bradmer receives FDA approval to proceed with Phase III clinical trial
8. Bradmer announces 2008 first quarter operational and financial results
9. Bradmer announces new additions to management team
10. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
11. Notice of Bradmer Pharmaceuticals Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Definitive Healthcare ... and healthcare providers, is pleased to announce the ... online database, now available for subscription, features detailed ... health system affiliations. , The Canadian database spans ... intelligence on over 750 hospitals. Each hospital ...
(Date:9/16/2014)... An experimental positron emission tomography (PET) ... a person is still alive, according to a case ... Mount Sinai, and at Molecular Neuroimaging (MNI) LLC in ... Translational Psychiatry. , Specifically, the study results suggest that ... designed to latch onto a protein called tau that ...
(Date:9/16/2014)... Terminsurancevirginia.com has released a new blog ... life insurance for obese clients. , Obese clients ... quotes. It is unlikely for applicants to be denied ... life insurance costs. , Having life insurance is ... Life insurance is available as temporary or permanent coverage ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Gary F. ... of China, has selected Worldwide Speakers Group for exclusive ... U.S. Secretary of Commerce and Governor of Washington, Locke ... authorities on U.S.-China relations, global expansion, and business growth. ... global competitiveness and how to grow an organization’s global ...
(Date:9/16/2014)... 2014 Representatives with safetyBUILT-IN ( ... the first phase of a safety-culture-development initiative for ... York, and just recently launched Phase II of ... now the third such facility where safetyBUILT-IN has ... safetyBUILT-IN Principal Eric Svendsen, Ph.D. “The first two ...
Breaking Medicine News(10 mins):Health News:Canadian Hospital Database Now Offered by Definitive Healthcare 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 2Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 3Health News:Neuroimaging Technique Identifies Concussion-Related Brain Disease in Living Brain 4Health News:Obese Clients Can Find Affordable No Exam Term Life Insurance at Terminsurancevirginia.com! 2Health News:Gary Locke, Former Ambassador to China, Selects Worldwide Speakers Group for Exclusive Lecture Representation 2Health News:safetyBUILT-IN Leads Safety-Culture Field-Coaching Effort 2
... a virtually eradicated disease that eats through people's skin, ... South America. ,WHO reported that it ... the skin and bone wasting disease Yaws. The disease ... a bacterial infection, can cause debilitating deformations, particularly in ...
... local and international experts, vaulting over a buffer between ... Central province, for the first time. This has created ... Nairobi. ,The buffer was created by the ... Organisation (WHO) and Food and Agricultural Organisation (FAO). ...
... risk of catching bird flu, as the deadly virus is most ... on cats in areas where outbreaks have occurred found that the ... the chilling prospect that the disease could soon easily be spread ... shows that should bird flu ever break out in Britain, cat ...
... predict disease outbreaks may want to tune into more weather ... finding out when an epidemic is imminent because they determine ... ,The techniques can help quicken the response to ... heat wave and global warming is adding urgency to such ...
... of Informatics-led team of researchers has constructed a model ... across the globe// by airliners. ,The study, ... and Containment Intervention," appears in the January issue of ... said to be the world's largest-scale epidemic simulation of ...
... A new study suggests that TEMPE, a topical anesthetic ... treatment for men with premature ejaculation and might be ... study is published in the February issue of the ... UK and Netherlands studied 54 men with premature ejaculation, ...
Cached Medicine News:Health News:Kenya: Alert As Virus Leaps Over Buffer Zone 2Health News:Kenya: Alert As Virus Leaps Over Buffer Zone 3Health News:Cat Owners at Risk of Bird Flu 2Health News:Experts Use Weather to Predict Disease 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 2Health News:Scientists Assess Risk of Flu Pandemic Spread Via Global Airlines 3Health News:TEMPE Spray Delays Ejaculation 2
(Date:9/16/2014)... Mass. , Sept. 16, 2014  Decision Resources Group finds ... from $14 billion in 2013 to over $18.2 billion in 2023 ... , Germany , Italy ... and Japan . TNF-alpha inhibitors will ... in the RA market, but growth will be constrained and patient ...
(Date:9/16/2014)... 16, 2014 Surgeons at The Children,s Hospital ... case report the first successful use of a SynCardia ... boy with failing Fontan circulation to bridge him to ... years old, the patient received a Fontan circulation procedure ... ventricle. "The Fontan operation is the final planned palliative ...
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
Breaking Medicine Technology:The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 2The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics 313-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2
... and KOS, Greece, June 29, 2007 /PRNewswire/ --,The ... treated patients on REVLIMID (lenalidomide) plus the,steroid dexamethasone ... The data are pooled from two large randomized,controlled ... patients,from nearly 100 clinical sites worldwide. These updated ...
... at the 11th International Myeloma Workshop ... of perifosine in,combination with bortezomib, dexamethasone ... relapsed/refractory multiple,myeloma, and as a single ... NEW YORK, June 29, 2007 /PRNewswire-FirstCall/ ...
Cached Medicine Technology:The European Myeloma Platform Reports New Survival data for,Revlimid Presented at the International Myeloma Workshop in Greece 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 2Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 3Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 4Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 5Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 6Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase,II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple,Myeloma and Waldenstrom's Macroglobulinemia 7
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: